Two Phase 3 trials show tildrakizumab is efficacious, well–tolerated in patients.
Until the 1990s, physicians had few options to offer their patients with moderate–to–severe psoriasis. Up to a quarter of patients with psoriasis suffer from these more aggressive cases that can affect anywhere from 10 to a 100 percent of the surface of the skin.

Now, two Phase 3 trials have demonstrated that a biologic agent called tildrakizumab is efficacious and well–tolerated in patients with moderate–to–severe chronic plaque psoriasis.

The findings appeared in the journal The Lancet and represent a major step forward in the treatment of the skin disorder.

“We have made a huge amount of progress in the treatment of moderate to severe psoriasis over the past 15 years,” said the paper’s lead author, Alexa B. Kimball, MD, President and CEO of Harvard Medical Faculty Physicians (HMFP) at Beth Israel Deaconess Medical Center (BIDMC) and a Professor of Dermatology at Harvard Medical School. “In these two trials, we tested whether this new, very targeted approach to a selected part of the inflammatory pathway would be effective in treating psoriasis, and it was – dramatically so.”

An antibody that targets only a very specific pathway, tildrakizumab belongs to a class of treatments called biologic agents, or biologics for short. Different from traditional pharmaceutical drugs, biologics are based on molecules that the body makes naturally – like antibodies – repurposed to treat disease.

The parallel double–blind randomized controlled studies, known as reSURFACE 1 and 2, tested an antibody called tildrakizumab for its ability to clear up and control psoriasis in patients with moderate to severe disease. Together, more than 1,800 patients were enrolled in trials conducted at 250 sites in Austria, Australia, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, the United Kingdom and the United States. Patients were randomized to one of three groups; one group received 200 mg tildrakizumab, one received 100 mg and one received an inactive placebo.

On average, patients started the study with 30 percent of their body covered with psoriasis; 12 weeks later, 65 percent emerged with skin that was clear or almost clear – a 75 percent improvement as measured by the standard Psoriasis Area Severity Index (PASI). Fewer than 10 percent of those given a placebo achieved this level of improvement.

“The breakthrough here is that we have continued to refine our treatments to those that are likely to be most effective against psoriasis but less likely to affect other important pathways at the same time,” Kimball said. “The study also suggests that the 12–week end point may be too early to see optimal efficacy. Patients may continue to improve and that’s going to be important to show over time.”